This website is a compilation of certain public statements made by Roche regarding Roche's offer to purchase Genentech.
The materials on this website are intended for the use of Roche's shareholders, employees and other constituencies. They are not an offer to purchase, or a solicitation of an offer to sell, any securities of Genentech or a solicitation of proxies or consents from any shareholder of Genentech.
In the event a transaction is approved by the independent directors of Genentech and submitted to a vote of Genentech shareholders, Genentech would file proxy and other materials with the U.S. Securities and Exchange Commission. These materials would contain important information regarding the transaction.
This site contains certain forward-looking statements. These forward-looking statements may be identified by words such as "believes", "expects", "anticipates", "projects", "intends", "should", "seeks", "estimates", "future" or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, including among others:
- pricing and product initiatives of competitors;
- legislative and regulatory developments and economic conditions;
- delay or inability in obtaining regulatory approvals or bringing
products to market;
- developments in financial market conditions, including the market
for acquisition financing and other capital markets and fluctuations
in currency exchange rates;
- uncertainties in the discovery, development or marketing of
new products or new uses of existing products, including without
limitation negative results of clinical trials or research projects
and unexpected side-effects of pipeline or marketed products;
- increased government pricing pressures or changes in third party
reimbursement rates;
- interruptions in production;
- loss of or inability to obtain adequate protection for intellectual
property rights;
- Litigation;
- the inherent uncertainties involved in negotiations with the
special committee of Genentech and that there can be no assurances
that a negotiated transaction will ultimately be agreed to or
consummated;
- potential difficulties in integrating the businesses of Genentech
and Roche, and that some or all of the anticipated benefits of
the proposed transaction may not be realized on the schedule contemplated
or at all;
- that future dividends are subject to the discretion of the board
of directors of Roche and a number of other factors, some of which
are beyond the control of Roche;
- the ability of Roche to generate cash flow to, among other things,
repay acquisition-related debt as currently contemplated;
- loss of key executives or other employees; and
- adverse publicity and news coverage.
The directors of Genentech who are also employees of Roche will not take part in the consideration of the proposed transaction by the Genentech board and accordingly are not permitted to comment or respond to questions regarding the transaction as representatives of Genentech.
For marketed products discussed in this site, please see full prescribing information on our website - www.roche.com. All mentioned trademarks are legally protected.
The passage of time and/or the occurrence of subsequent events can render the materials on this website inaccurate or incomplete. Viewers of this website should consider the dates of issuance of all materials on this website and understand that Roche assumes no obligation to update or correct the materials on this website, whether as a result of new information, future events or otherwise.